Fig. 1From: Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancerBaseline images (left) compared with 9 week CT scan (right) showing reduction in target lesion size with anti-PD-1 therapyBack to article page